Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [4]. Core Insights - The pharmaceutical and biotechnology sector is experiencing a significant data catalyst window with the upcoming AACR annual meeting, which is expected to enhance the global competitiveness of Chinese innovative drugs [5]. - The industry index declined by 1.26%, outperforming the CSI 300 index, with notable gains in medical research outsourcing and chemical preparations [2][13]. - The overall PE ratio for the pharmaceutical and biotechnology industry is 29.30x, down from 30.34x, indicating a valuation decline below the average [17]. Industry Review - The report highlights that the innovative drug sector is currently the core focus, supported by favorable domestic policies such as the NMPA's "Spring Rain Action" to promote clinical innovation in medical devices [4][5]. - The total amount of innovative drug licensing transactions in China exceeded $60 billion in the first three months of 2026, indicating a strong global recognition of Chinese innovative drug assets [5]. - The report suggests focusing on companies with core technology platforms and differentiated pipeline layouts, particularly those expected to achieve positive catalysts at major academic conferences like AACR [5]. Important Industry News - The NMPA has initiated a three-year "Spring Rain Action" to support the transformation of clinical innovation in medical devices [21][26]. - Johnson & Johnson's oral IL-23R antagonist "Icotrokinra" has been approved by the FDA, marking it as the first of its kind globally [41]. - Novo Nordisk's weekly insulin "Awiqli" has received FDA approval, providing a new treatment option for type 2 diabetes patients [44]. - AstraZeneca and Amgen's TSLP monoclonal antibody "Tezepelumab" has been approved in China, making it the first of its kind domestically [46]. Company Dynamics - Novartis plans to invest over 3.3 billion RMB in China to enhance its R&D, production, and operational capabilities [48].

| 证券代码：300401 | 证券简称：花园生物 公告编号：2026-012 | | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | 浙江花园生物医药股份有限公司 关于子公司取得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江花园生物医药股份有限公司（以下简称"公司"）全资子公司浙江花 园药业有限公司（以下简称"花园药业"）于近日收到国家药品监督管理局核 准签发的"多索茶碱片"的《药品注册证书》。具体情况公告如下： 一、药品基本情况 4、规格：0.2g\0.4g 5、上市许可持有人/生产企业：浙江花园药业有限公司 6、药品批准文号：国药准字H20263657\国药准字H20263658 7、药品批准文号有效期：至2031年03月16日 二、对公司的影响 多索茶碱片主要用支气管哮喘、喘息性慢性支气管炎及其他支气管痉挛引 起的呼吸困难。据米内网数据显示，多索茶碱片2024年公立医疗机构市场规模 约为1.29亿元。 根据国家药监局《关于仿制药质量和疗效一致性评价工作有关事项的公 告》(2017年第100号)相 ...

Major Announcements - Farsen announced that it does not engage in "special optical fibers," "fiber sensing," or related businesses, and may apply for a trading suspension if stock prices continue to rise [1] - COSCO Shipping has suspended new bookings for related routes due to escalating conflicts in the Middle East, affecting several countries [2] Financial Performance - Muxi Co. expects a net loss of 90.76 million to 182 million yuan in Q1 2026, but revenue is projected to grow by 24.84% to 87.26% year-on-year [3] - Shanghai Electric received approval for two offshore wind power projects, which will enhance its green transition and increase clean energy share [4] - Xiamen Tungsten's revenue for January-February 2026 is expected to grow by 60% to 110% year-on-year, driven by rising raw material prices and increased sales [8] - Qiangyi Co. reported a 157.9% year-on-year increase in revenue for January-February 2026, attributed to strong demand in AI computing and the semiconductor industry [9] - Aerospace Intelligence reported a net profit of 881 million yuan for 2025, a year-on-year increase of 11.24% [10] - Yutong Bus sold 1,806 units in February 2026, a 14.96% increase year-on-year [11] Corporate Actions - China National Offshore Oil Corporation has cumulatively increased its stake in the company by 402.79 million yuan [16] - Huayuan Bio announced a temporary shutdown of its cholesterol production line for maintenance, expected to last no more than 45 days [7] - Zhi Gong Technology's shareholder plans to reduce its stake by up to 1.35% due to funding needs [14]

| 证券代码：300401 | 证券简称：花园生物 公告编号：2026-011 | | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | 浙江花园生物医药股份有限公司 关于全资子公司胆固醇产线停产检修的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏 浙江花园生物医药股份有限公司（以下简称"公司"）全资子公司浙江花园营养 科技有限公司（以下简称"花园营养"）将对胆固醇产线进行停产检修。现就相关情 况公告如下： 二、临时停产期间的安排 花园营养对部分生产线进行停产检修，有助于提高产线设备的稳定性。停产检修 期间，除生产环节外，公司市场拓展、客户对接等其他经营活动均保持正常开展。 三、对公司的影响及风险提示 除花园营养胆固醇产线停产外，公司其他业务正常开展。本次临时停产检修预计 不会对公司经营业绩产生重大不利影响。公司将持续关注本次停产的后续进展，严格 按照相关监管规定及时履行信息披露义务，敬请广大投资者理性投资，注意风险。 特此公告。 浙江花园生物医药股份有限公司董事会 2026年3月4日 一、临时停产检修情况 花园营养根据年度生产经营 ...

| 证券代码：300401 | 证券简称：花园生物 | 公告编号：2026-010 | | --- | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | | 浙江花园生物医药股份有限公司 关于可转换公司债券 2026 年付息的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、"花园转债"（债券代码：123178）将于2026年3月6日按面值支付第三年利息， 每10张"花园转债"（面值1,000.00元）利息为10.00元（含税）。 2、债权登记日：2026年3月5日（星期四） 3、付息日：2026年3月6日（星期五） 4、除息日：2026年3月6日（星期五） 5、本次付息期间及票面利率：计息期间为2025年3月6日至2026年3月5日，票面利 率为1.0%。 4、可转换公司债券上市量：120,000.00万元（1,200万张） 5、可转换公司债券上市地点：深圳证券交易所 6、可转换公司债券上市时间：2023年3月23日 6、本次付息的债权登记日为2026年3月5日。凡在2026年3月5日（含）前买入并持 有本期 ...

Core Viewpoint - Garden Biologics has shown fluctuations in financing activities and stock performance, with a notable decrease in net profit and revenue in recent financial reports [1][2]. Financing Activities - On February 25, Garden Biologics experienced a financing buy-in of 37.78 million yuan, while the financing repayment amounted to 57.76 million yuan, resulting in a net financing outflow of 19.98 million yuan [1]. - The total financing and margin trading balance for Garden Biologics reached 789 million yuan, with the financing balance accounting for 8.47% of the circulating market value, indicating a high level compared to the past year [1]. - In terms of securities lending, 500 shares were repaid, and 800 shares were sold on February 25, with a selling amount of 13,700 yuan, while the securities lending balance was 2.31 million yuan, also at a high level compared to the past year [1]. Company Overview - Zhejiang Garden Biologics Co., Ltd. was established on December 18, 2000, and went public on October 9, 2014. The company focuses on developing, producing, and selling products related to a complete vitamin D3 industry chain [1]. - The main revenue sources for the company include vitamin products (47.41%), pharmaceuticals (30.22%), lanolin and its derivatives (20.93%), and other minor categories [1]. Shareholder Information - As of February 10, the number of shareholders for Garden Biologics increased by 2.92% to 24,300, while the average circulating shares per person decreased by 2.84% to 22,025 shares [2]. - Cumulatively, the company has distributed 446 million yuan in dividends since its A-share listing, with 178 million yuan distributed over the past three years [3]. - Among the top ten circulating shareholders, the Southern CSI 1000 ETF holds 3.48 million shares, a decrease of 48,400 shares from the previous period [3].

Group 1 - The core point of the article is that Garden Biologics reported a total of 24,273 shareholders as of February 10, 2026 [2]

Group 1 - The stock price of Huayuan Bio (300401) experienced significant fluctuations in the past week, with a peak increase of 5.98% on February 6, closing at 19.15 yuan, and a total market value of 95.65 billion yuan as of February 12 [1] - The stock showed a trading range of 12.45% and a high turnover rate, indicating active trading, with a net outflow of 39.57 million yuan from institutional investors and a net inflow of 39.57 million yuan from retail investors on February 12 [1] Group 2 - Huayuan Bio is recognized as a leader in the vitamin segment and has gained market attention as a hot stock in the chemical sector, with significant holdings by Southern Fund's CSI 1000 ETF, which owns 347.85 thousand shares (0.65% of circulating shares) but reduced its holdings by 48.4 thousand shares in the third quarter [2] - The chemical sector, particularly phosphates and vitamins, has been driven by policy and demand, with Huayuan Bio being highlighted for its vitamin D3 supply chain [2] Group 3 - Institutional ratings for Huayuan Bio are generally neutral, with a target price of 22.00 yuan, indicating a potential upside of 21.48% from the latest price [3] - The forecast for net profit growth is modest, with a projected increase of 0.18% for 2025 and a more substantial growth of 40.35% expected in 2026, while the current price-to-earnings ratio (TTM) stands at 31.69 [3] - The proportion of institutional holdings is relatively low at 0.11%, and the frequency of institutional research is average [3]

Group 1 - Garden Biologics' stock increased by 5.06%, reaching 18.68 CNY per share, with a trading volume of 356 million CNY and a turnover rate of 3.65%, resulting in a total market capitalization of 10.152 billion CNY [1] - The company, Zhejiang Garden Biologics Co., Ltd., was established on December 18, 2000, and went public on October 9, 2014. Its main business focuses on developing, producing, and selling products related to a complete vitamin D3 industry chain [1] - The revenue composition of the company includes vitamin products at 47.41%, pharmaceuticals at 30.22%, lanolin and its derivatives at 20.93%, sales of raw materials and others at 1.01%, rental income at 0.31%, other trade products at 0.10%, and medical devices at 0.01% [1] Group 2 - Southern Fund's Southern CSI 1000 ETF (512100) is among the top ten circulating shareholders of Garden Biologics, having reduced its holdings by 48,400 shares to 3.4785 million shares, representing 0.65% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a latest scale of 78.996 billion CNY. Year-to-date returns are 8.61%, ranking 1564 out of 5569 in its category, while the one-year return is 34.61%, ranking 1862 out of 4295 [2] Group 3 - The fund manager of Southern CSI 1000 ETF (512100) is Cui Lei, who has been in the position for 7 years and 98 days. The total asset scale under management is 137.02 billion CNY, with the best fund return during the tenure being 251.88% and the worst being -15.93% [3]

Group 1 - The company has no plans to acquire Furuixi Pharmaceutical as stated on the interactive platform [1]